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Purpose: This clinical study was designed to prospectively evaluate the acute and moderately-late cardiac and lung
toxicities of intensity modulated radiation therapy delivered by helical tomotherapy (IMRT-HT) for locoregional
breast radiation treatment including the internal mammary nodes (IMN).
Material/methods: 30 patients with stage III breast cancers have been accrued in this study. All patients received
adjuvant chemotherapy. Target volumes were defined as follows: the PTV included breast/chest wall, axillary level II,
III, infra/supraclavicular, IM nodes CTVs plus 3 mm margins. The heart with subunits and the lungs were defined as
critical organs. Dose to PTV was 50 Gy in 25 fractions. Acute toxicities were assessed every week and 2 weeks post
treatment using the CTCAE v3.0.scale. The moderately-late toxicities were assessed clinically plus by cardiac myoview
perfusion tests scheduled at baseline, 3 and 12-month follow-up, as well a CT chest at the 6 month follow-up. The data
analysis is descriptive.
Results: All participants completed the 5-week course of radiation without interruption. Skin erythema was modest
and mainly grade 1–2 between the 3rd and the 5th week of radiation treatment. Only 4/30 patients experienced grade
3 skin reactions, mostly seen 2 weeks post radiation. Only 5 patients demonstrated grade 1 or 2 dyspnea, but 3 of them
already had symptoms pre-radiation treatment. With a median follow-up of 58 (24–76) months, there have been
infrequent moderately-late side effects. Most were grade 1 and were sometimes present at the baseline assessment.
Cardiac myoview tests done at baseline and 1-year follow-up for 15 out of 18 left sided breast cancers did not show
any abnormalities related to radiation. The 6-month follow-up chest CT-scans done for 25 out of 30 patients showed
minimal anterior lung fibrosis for 7 patients and were completely normal for the other 18. No locoregional recurrence
has been recorded and the 5-year survival is 78% (95% CI: 70-97%).
Conclusion: IMRT-HT for locoregional breast radiation is very well tolerated with minimal acute or moderately-late side
effects. Cardiac and respiratory tests did not show any strong evidence of significant treatment related abnormalities.
Trial registration: clinicaltrials.gov: NCT00508352.
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To irradiate the breast/chest wall and nodal areas, while
minimizing the volume of normal tissue within the plan-
ning target volume (PTV) can be challenging, in particular
if the internal mammary nodes (IMN) are included in the
clinical target volume (CTV). Previous clinical trials and
meta-analyses have shown that the benefits of locoregional
radiation may have been overshadowed by the increased* Correspondence: jcaudrelier@ottawahospital.on.ca
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unless otherwise stated.risk of mortality, mainly related to cardiac injury [1-3].
There is evidence that patients treated more recently with
updated techniques have no or a lower risk of increased
late cardiac mortality [4-6]. However, these patients
may still have risks of cardiac morbidity that may also be
increased by anthracycline-based chemotherapy regimens
potentially combined with trastuzumab [7-10]. As a result,
and as the risk/benefit ratio for locoregional radiation is
tight, there is significant variation between centres in the
use of locoregional radiation, especially when the IMN
is included in the target volume [11]. Two clinical trials
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inclusion of the IMN. Both studies have been completed
and the results have been reported in abstract form. Both
showed decreasing risks of locoregional recurrence and of
metastasis in the group of women treated by locoregional
radiation [12,13]. Thus, there is some evidence suggesting
that a group of women with breast cancer may benefit from
IMN radiation.
Various radiation techniques have been used to encom-
pass the breast/chest wall and nodes including the IMN in
order to reduce the dose to the normal tissues including
the heart. In recent years, several dosimetry papers have
evaluated the benefits of intensity modulated radiotherapy
(IMRT) against more conventional 3D techniques [14-23].
They suggest that IMRT results in similar target volume
coverage, better target volume conformality and reduced
volume of normal tissues irradiated to high dose. Our
group published a dosimetric study comparing IMRT-HT
versus 3D conventional technique and found similar
results in favour of IMRT [23]. Following this dosimetric
study, a pilot clinical study was implemented to evaluate
the clinical outcomes of patients treated with IMRT-HT
for locoregional breast radiation, including the IMN. The
eligible women included were those with stage III breast
cancer considered at high risk of locoregional recurrence.
The goal of this study was to evaluate the acute plus the
moderately-late toxicities, with a focus on the heart and
lungs. We now report the results, after a minimum
follow-up of 47 months in the group of patients still alive.
Patients and methods
Thirty women with stage III breast cancer, median age of
52 years [33–72], have been accrued in this prospective
pilot study between January 2007 and November 2009.
Women were eligible if there were any of the following
high-risk pathological features present at time of surgery:
any pT and pN2, or pT3-4 and pN0-1 with a central/
medial location of the tumour. Of the 30 patients, 27 were
eventually staged pN2 or pN3 and the last 3 patients who
were pN1 had a primary tumour staged pT3. Mastectomy
was performed on 20 patients and breast conserving
surgery on 10. Eighteen patients had left sided and 12
patients had right-sided breast cancer. All patients received
adjuvant chemotherapy, which was completed before start-
ing adjuvant radiation. Patients with Her2neu positive
status who were candidates for trastuzamab were not in-
cluded to avoid confounding factors in evaluation of cardiac
toxicity. The main chemotherapy regimens were FEC100-
Docetaxel (17 patients) and AC-Paclitaxel (10 patients).
Target volumes were defined on 3 mm CT-scan slices
with IV contrast. PTV included the breast/chest wall,
axillary level II, III, infra/supraclavicular, and IM nodal
CTVs plus a 3 mm margin. A total of 4 radiation
oncologists accrued patients and defined the targetvolumes, using an in-house breast cancer/nodal atlas
based on some anatomy books and based on anatomy
of previous patients treated. In our center, since 2003 and
on yearly basis, an average number of 250 locoregional
breast 3D conformal radiation planning, with targeting
of nodal areas, is done. The heart (with right and left
ventricles and coronary arteries) plus the lungs, oesophagus
and thyroid were defined as normal tissue. Dose prescribed
to the Planning Target Volume (PTV) was 50 Gy in 25 frac-
tions. Dose constraints on PTV and on normal tissue were
defined at time of the dosimetric study and have been
previously published [22]. The goal was to deliver 50 Gy
to at least 90% of the PTV.
Clinical outcomes follow-up
A radiation oncologist and/or a clinical research assistant
assessed the acute toxicity every week for the duration of
treatment and 2 weeks post treatment, using the CTCAE
v3.0.scale. Follow-ups were scheduled at 3 months post
radiation and then every 6 months thereafter.
Smoking history, cardiac and lung comorbidities were
collected. Eleven patients had a smoking history with
tobacco consumption from 3 to 45 pack-years, 7 of them
having a tobacco consumption at least of 10 pack-years.
The prior cardiac history was significant for: 1 patient with
valve surgery, 1 patient with bypass surgery, 1 patient with
treated arrhythmia and high blood pressure (HBP), plus 5
patients with treated HBP. The respiratory history was
significant for: 1 patient with treated chronic obstructive
pulmonary disease (the heaviest smoker), and 4 patients
with treated asthma.
Cardiac function and radiation effects were evaluated
using persantine myoview perfusion and left ventricular
function test performed at baseline, 3 and 12-month
follow-up. Images for tomographic myocardial perfusion
were acquired following persantine stress (50 mg IV) and
at rest and by using IV Technetium-99 m tetrofosmin
(99mTc) (334 MBq at rest and 1070 MBq at peak stress).
Both the myocardial perfusion plus the left ventricular
function at rest and post stress were evaluated. The myo-
view tests were initially done with 99mTc, but following
the radioactive metabolite crisis and shortage of 99mTc,
follow-up myoview tests were done with Thallium-201
chloride (Tl-201) administered intravenously at peak
vasodilation (130 MBq). Cardiac function interpret-
ation combined rating ECG, left ventricular function
and myocardial perfusion as normal or not. A global
score of zero (if no abnormalities at all) or 1 (if at least
1 abnormality reported) was attributed to each patient.
When the global score was 1, tests were reviewed in
detail to precisely define the abnormalities reported.
The evaluation of pulmonary toxicity was mainly clinical
but a CT scan of the chest was scheduled at the 6-month
follow-up to evaluate radiologic fibrosis.
Table 1 Metrics recorded from DVHs
Treatment planning metrics
PTV
V47.5 97.6% ± 1.5%
V53.5 5.9% ± 6.8%
Ipsilateral lung
Mean dose 10.2Gy ± 1.1Gy
V5 49.8% ± 10.4%
V20 16% ± 3.4%
Controlateral lung
Mean dose 5.3Gy ± 0.6Gy
V5 43.7% ± 8.9%
V20 0.5% ± 1.2%
Controlateral breast
Mean dose 4.0Gy ± 0.8Gy
V5 30.3% ± 15.7%
V10 2.3% ± 4.1%
Heart Right side Left side
Mean dose 7.8Gy ± 1.1Gy 8.0Gy ± 1.2Gy
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The main objective was to assess the feasibility of IMRT
locoregional breast radiation by evaluating the clinical
outcomes (radiation side effects). The precision with which
the incidence of grade 3 adverse events can be estimated
with n = 30 was measured by the 95% confidence interval
around the proportion of adverse events, applying a
normal approximation to the confidence interval calcu-
lation. Even at the maximum of a 50% proportion of
adverse events, the confidence interval around the esti-
mate of the proportion of adverse events equals to
33.7%, which provides clinically meaningful estimates.
Most of the results are presented in a descriptive way.
The survival curve has been estimated by the Kaplan
Meier method. Comparison of means, if indicated, was
done by a sample t-test. Statistical tests were done
using XLSTAT 2012.5.02.
This clinical trial was approved by the ethics committee
of the Ottawa Hospital Research Institute, patients signed
informed consent and the study was registered in the
clinicaltrials.gov database with the following identifier:
NCT00508352.V25 1.9% ± 1.4%* 3.7% ± 1.9%*
LAD artery Right side Left side
Dose max 33.3Gy ± 13.3Gy 26.7Gy ± 15.7Gy
Median dose 13.3Gy ± 5.6Gy 10.8Gy ± 7.8Gy
RCA artery Right side Left side
Dose max 30.3Gy ± 8.6Gy 27.0Gy ± 12.4Gy
Median dose 14.0Gy ± 4.9Gy 12.4Gy ± 5.7Gy
LCx artery Right side Left side
Dose max 8.6Gy ± 4.4Gy 8.8Gy ± 3.2GyResults
In Table 1, a summary of dosimetric metrics is reported.
The doses to the PTV, the lungs, heart and contralateral
breast were within the range of what is expected with
the IMRT rotational beam technique. We note that for the
heart and the coronary arteries, the mean dose, median
dose and V25 were globally not different between patients
treated to the right or the left side. Only the heart V25 was
slightly and significantly higher for the left side.Median dose 4.4Gy ± 1.5Gy 4.5Gy ± 1.7Gy
Vx = Volume of target/normal tissue receiving at least x Gy. Values reported
are average ± standard deviation of metrics recorded.
LAD: left anterior descending artery, RCA: right coronary artery,
LCx: left circumflex artery.
*Comparison of means significantly different between the right and left side
treated. t-test, p = 0.01.Acute toxicity
All patients completed the 5-week course of radiation
without interruption. Skin erythema was modest and
mainly grade 1 during the 3rd and 4th week (22/30 and
24/30 patients, respectively), and grade 2 during the 5th
week (22/30 patients). Only 4/30 patients experienced
grade 3 (any moist desquamation area) erythema, mostly
recorded 2 weeks post radiation. Only 5 patients demon-
strated grade 1 or 2 dyspnea but 3 of them already had
symptoms pre-irradiation at baseline assessment. One
patient had developed acute respiratory distress syndrome
pre-irradiation during delivery of adjuvant taxane-based
chemotherapy and was managed in the intensive care unit.
A second patient developed bronchiolitis obliterans post
taxane-based chemotherapy that merited an evaluation by
a respirologist. Neither of these women developed any
acute respiratory symptoms during radiation treatment.
Eleven patients showed grade 1 temporary dysphagia from
esophagitis.Moderately-late effects
The median follow-up of the whole group, including the
deceased patients, is 58 (24–76) months. The evolution
of the major moderately-late side effects is summarized
in Table 2. Skin reactions, breast/chest-wall pain, respira-
tory and sensori-motor symptoms have been infrequent,
and mostly grade 1. They were sometimes already present
at baseline assessment. Six patients underwent breast
reconstruction post mastectomy and none developed any
significant complications, including no arm lymphedema
recorded from physical examination or from arm mea-
surements done by a nurse. One patient was diagnosed
with acute leukemia 24 months post radiation treatment
and is currently in complete remission post treatment. Her
adjuvant chemotherapy regimen was FEC100-Docetaxel.
Table 2 The most frequent moderately-late side effects recorded
Moderately-late side effects
Adverse events Grade Baseline 3 months 6 months 12 months 18 months 24 months 30 months
30 pts 30 pts 30 pts 29 pts 28 pts 27 pts 26 pts
Erythema pigmentation Grade 0 6 14 18 22 23 22
Grade1 23 16 11 6 4 4
Grade2 1 0 0 0 0 0
Induration fibrosis Grade 0 23 23 22 24 23 22
Grade 1 6 6 7 4 4 4
Grade 2 1 1 0 0 0 0
Telangiectasia Grade 0 30 30 29 26 23 21
Grade 1 0 0 0 2 4 4
Grade 2 0 0 0 0 0 1
Breast/chest wall pain Grade 0 23 13 16 17 18 20 20
Grade 1 6 16 13 12 9 6 6
Grade 2 1 0 1 0 1 1 0
Grade 3 0 1 0 0 0 0 0
Cough/dyspnea Grade 0 27 28 28 26 25 26 26
Grade 1 3 2 2 3 2 1 0
MSK upper limb treated/
neurosensitive symptoms
Grade 0 18 24 25 25 25 25 26
Grade 1 10 5 4 4 3 3 1
Grade 2 2 1 1 0 0 0 0
The only grade 2 reported at 30 months is a cosmetic one. Note that the number of grade 1 toxicity is low at 30 months, with significant decreased number over
time for pain and skin erythema/pigmentation.
We can note that the number of grade 1 or 2 side effects for cough/dyspnea and neuro-muscular symptoms are not very significantly different between baseline
and early follow-up assessments.
MSK: musculoskeletal.
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the radiated side 30 months post radiation treatment. This
patient had other lung cancer risk factors. The primary
tumour was localized in an area that was covered by 40
to 50 Gy. It is possible that this small cell lung cancer
was radiation induced. However, this causality is not
specific to the IMRT technique as a tangential radiation
beams technique would have covered the same area with
the 40 to 50 Gy isodoses.
Myoview scintigraphy tests
Women were scheduled for baseline, 3 and 12-month
follow-up scintigraphy but some women declined the
initial tests and some declined any follow-up tests, mostly
because of the discomfort caused by the persantine injec-
tion used to simulate stress. The number of tests done
and abnormalities reported are summarized in Table 3.
Abnormalities have been recorded for 6 women, 4 radiated
on the right side and 2 on the left. For 5 patients, the
perfusion abnormalities are not related to the radiation
treatment. Three were present at baseline and 2 at
follow-up were related to imaging artefacts according
to cardiology assessment. Only 1 patient’s abnormalities
were possibly related to radiation. This patient had severalcardiac comorbidities (arrhythmia, HBP, smoking habits)
and her cardiac radiation doses were the following: heart
mean dose:7.8Gy, V25:4%; left ventricle median dose:4.4Gy
[2.2-28.9], V30:0%; LAD artery median dose:26Gy [3.7-43.5].
Following a gastrointestinal surgical procedure, this patient
died from congestive heart failure post atrial flutter.
Pulmonary toxicity
As summarized in Table 2, no significant late clinical
pulmonary toxicity has been recorded. A maximum
number of 3 patients experienced a grade 1 dyspnea or
cough from 3 and up to the 12 month follow-up. The 2
patients who needed respirologist evaluation were all
seen during or at the end of chemotherapy. At 30 months,
all 26 remaining patients had no respiratory symptoms. A
6-month follow-up CT chest has been done for 25 out of
30 patients. For 18 patients, the CT chest was completely
normal and for the other 7, the CT chest showed a min-
imal anterior fibrosis (grade 1 fibrosis).
Recurrences/survival
No loco-regional recurrence has been diagnosed. Five pa-
tients have been diagnosed with distant recurrent disease.
One patient developed a contralateral breast cancer with
Table 3 Patients with myoview perfusion cardiac tests having at least one abnormal study
Myoview perfusion cardiac tests
Baseline 3 months F-up 12 months F-up
Patient number and side radiated 26 tests 99 m Tc:
21 Tl-201: 5
21 tests 99 m Tc:
13 Tl-201: 8
23 tests 99 m Tc:
9 Tl-201: 14
Comments
1: Right P P P History of cardiac surgery
2: Right P ? 0 Artefact
3: Left P 0 0 Artefact
4: Right 0 P ? No cardiac event
5: Left 0 ? P* *positive test 30 months post radiation
6: Right 0 0 P Artefact
*Note that the patient number 5 had a test positive 30 months post radiation. This patient declined any per protocol follow-up myoview test.
P: perfusion abnormality, 0: no perfusion abnormality, ?: test not done.
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of radiation treatment. This was in the context of a BRCA1
gene mutation. The same patient later developed metastatic
disease. Four patients have been diagnosed with bone me-
tastasis at least after 6 months of follow-up. Six deaths have
been recorded: 4 patients from progression of metastatic
breast cancer, 1 patient from a lung cancer and one due to
a cardiac event post surgical procedure. The estimated
Kaplan Meier survival at 5 years is 78% (CI 95%: 70-97%).
Discussion
Planning of locoregional breast radiation is challenging,
particularly when the IMN is included. IMRT techniques
for locoregional breast radiation have been evaluated in
multiple dosimetric papers. However, publications of clin-
ical studies of such locoregional breast radiation techniques
are still limited. Within the frame of this pilot study
involving a limited number of patients and with the
dose constraints used for PTV and normal tissue, the
acute toxicities were modest. The rate and the degree
of erythema were similar to the acute skin reactions re-
ported in one recent clinical trial evaluating intact breast
IMRT [24]. The moderately-late skin side effects such as
erythema and/or pigmentation were also decreasing over
time and only a small number of patients showed any
residual skin effects.
Lung tolerance
Clinically significant symptomatic radiation pneumonitis
occurs in approximately 1–5% of patients irradiated for
breast cancers [25]. One of the major concerns (explaining
the low rate of accrual) with this pilot trial was the possi-
bility of an increased risk of severe subacute respiratory
symptoms related to the IMRT rotational beam technique.
This technique results in an increase in the volume of
lung receiving a low dose of radiation (<10Gy). Severe
respiratory toxicity has been reported for mesothelioma
patients treated by post operative IMRT when the mean
lung dose and V20 and V5 were increased [26]. Howeverin our group of patients, acute or moderately late lung
effects were not seen. Most of the respiratory symptoms
recorded were already present at baseline and some were
partly related to the taxane-based regimen. These results
may fit with some published data suggesting that reducing
the volume of lung receiving high dose of radiation
(≥40Gy) and reducing the mean lung dose decrease the
risks of radiation pneumonitis [27]. The CT chest at the
6-month follow-up done for 25 (83%) of the patients
was reported normal for 18 (72%) of them. The others
showed minimal anterior fibrosis. Thus, we may postulate
that locoregional IMRT was very well tolerated regarding
pulmonary side effects. It could be noted that the average
DVH values recorded for lungs in our clinical study are in
the range of values recommended for radiation therapy
post pneumonectomy for mesothelioma in the last Quan-
titative Analysis of Normal Tissue Effects in the Clinic
(QUANTEC) review [28].
Cardiac effects
Cardiac perfusion defects of up to 30% have been seen
on follow-up scintigraphy perfusion tests for irradiated
left breast cancer patients [29-31]. Myoview tests have
been used as a surrogate marker of possible cardiac injury
from radiation treatment. Fifteen out of eighteen left sided
breast cancer patients had baseline, 3 and 12 month
follow-up myoview tests and none of them detected a
significant perfusion abnormality. The only patient who
developed cardiac problems was diagnosed with an ab-
normal test at 30 months post radiation treatment. It is
unclear if these abnormalities and subsequent cardiac
problems were related to previous breast cancer treatments,
but we cannot completely exclude radiation treatment
causality for this patient. A recent study reported a per-
cent increase of major coronary event by 7.4% for every
1 Gy of mean cardiac dose [10]. For a mean cardiac
dose of 8 Gy (the mean cardiac dose recorded in our
study for women radiated on the left or right side) the
estimated percent increase of major coronary event is
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Darby et al. paper can be used for locoregional breast
radiation with IMRT rotational beam technique. Their
study reported only the mean cardiac dose, but not the
volume of heart receiving above 25 Gy and/or close to
the prescription dose. Radiation by a combination of
tangent beams treats a larger volume of heart with a dose
equal or superior to 25 Gy, compare to IMRT rotational
beam technique. On the other hand, IMRT rotational beam
technique will radiate a larger volume of heart to a dose
less than or equal to 10 Gy, and as a result the mean
cardiac dose will be higher compared to the tangential
beam radiation technique. We think that when evaluating a
locoregional breast radiation planning, the mean cardiac
dose is not the only factor to consider and that the V25
and/or V30, V40 are also important metrics. From the per-
fusion myoview tests results, we also note that a mean car-
diac dose around 6–8 Gy seems to be safe for breast cancer
women, if we can achieve a V25 below 5% and a V30 below
2.5%. We do not believe that the mean cardiac dose is the
only metric to meaningfully compare 3D planning using
tangent beams and the IMRT rotational beam technique.
As stated above and due to the shortage of radionuclides,
99mTc was replaced by Tl-201. One may argue that this
may have altered the results of the myoview tests. However,
the ROBUST study compared the performances of 3 radio-
nuclide myocardial perfusion tracers for clinical practice in
a large population of 2560 patients. That study concluded
that all tracers performed well in clinical terms, with high
sensitivity and specificity for angiographic stenosis and no
differences in accuracy between the tracers [32]. Therefore,
we may reasonably suggest that the negativity of myoview
tests is likely due to the sparing of cardiac structure includ-
ing the coronary arteries from a high dose of radiation.
Conclusion
Within the frame of this prospective evaluation done on
a limited number of patients, IMRT-HT for locoregional
breast radiation has been feasible and very well tolerated
with minimal acute or moderately-late side effects. Cardiac
and respiratory tests did not show any significant treatment
related abnormalities. In our cancer centre, IMRT-HT
is now a routine option when a complex locoregional
radiation is indicated. Since 2011, we have also have
implemented volumetric linac based IMRT.
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